Egetis Capital Markets Day on October 13: program and registration procedures


Stockholm, Sweden, October 6, 2022. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today announced the agenda and registration details for the company’s Capital Markets Day on Thursday, October 13, 2022in Stockholm, Swedenfor investors, analysts and the media.

Time: Thursday, October 13, 2022at 1:00 p.m. – 4:00 p.m. CEST
Venue: Bank Erik ThinkingApelbergsgatan 27, Stockholm, Sweden
Registration (to attend in person): please register here
Webcast (no pre-registration required): Please follow this link

During the event, the company will provide an update and review of its strategy and pipeline. Presentations will focus on the Company’s drug candidates and the unmet medical needs they will address, development plans, business opportunities and additional activities to create and enhance long-term shareholder value. Presentations will be made by members of Egetis’ management team and board, as well as invited thought leaders. Presentations will be in English. The webcast will also be available on the Egetis webpage www.egetis.com after the event.

Agenda

Time Matter Presenter(s)
13:00 Welcome, Business Strategy and Overview Nicklas WesterholmCEO
13:15 MCT8 deficiency and clinical experience with Emcitate Doctor Edouard Visser, Erasmus Medical Center
13:40 Development paths for Emcitate in Europe and the United States Doctor Peder WalbergConsulting Operations Director
13:55 Q&A: MCT8 deficiency & Emcitate development Visser, Walberg, Sjöblom, Westerholm
14:10 Global Marketing Plans Emcitate Doctor Henrik CrookVP Sales
14:20 Market access and commercialization in the United States Sara Melton, President Egetis North America
2:30 p.m. Questions and answers : Emcitate marketing Walberg, Krook, Melton, Westerholm
14:45 To break
15:00 Paracetamol overdose and clinical experience with Aladote Teacher. James dear, Edinburgh University
15:20 Development paths for Aladote in Europe and the United States Doctor Kristina SjoblomCMO
15:30 Business opportunity for Aladote Doctor Henrik CrookVP Sales
15:35 Aladote Questions and answers Cher, Sjöblom, Krook, Westerholm
15:45 Summary of the day Nicklas WesterholmCEO
15:55 Final remarks Thomas Lönngren, Chairman of the Board
4:00 p.m. End

© Modular Finance, source Nordic press releases

All news about EGETIS THERAPEUTICS AB (PUBL)

2022 sales 27.9 million
2.53 million
2.53 million
Net income 2022 -144M
-13.1M
-13.1M
Net cash 2022 150M
13.7 million
13.7 million
PER 2022 ratio -6.60x
2022 return
Capitalization 1,033 million
93.9 million
93.9 million
EV / Sales 2022 31.7x
EV / Sales 2023 13.4x
# of employees 15
Floating 99.0%

Chart EGETIS THERAPEUTICS AB (PUBL)


Duration :

Period :




Egetis Therapeutics AB Technical Analysis Chart (publ) |  MarketScreener

Trending Technical Analysis EGETIS THERAPEUTICS AB (PUBL)

Short term Middle term Long term
Tendencies Bullish Neutral Bearish




Evolution of the income statement

Sale

To buy

Medium consensus TO BUY
Number of analysts 2
Last closing price SEK4.82
Average target price SEK16.50
Average Spread / Target 243%